Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.

Clinicoecon Outcomes Res · 2017 · PMC5237592 · PMID 28138260

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

8 , 9 Similarly, there were also two tinzaparin trials that failed to reach statistical significance, one being a large well-powered multinational study that enrolled 900 cancer patients. 10 , 11 The only LMWH to have demonstrated a statistically and clinically meaningful benefit in terms of VTE risk reduction has been dalteparin.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.